Journal of the European Academy of Dermatology and Venereology最新文献

{"title":"Combining treat-to-target principles with patient choice: A small step AHEAD in the right direction","authors":"Hywel C. Williams","doi":"10.1111/jdv.20298","DOIUrl":"10.1111/jdv.20298","url":null,"abstract":"<p>The treat-to-target approach specifies optimum treatment targets such as blood glucose levels that result in health benefit. Setting single targets for complex inflammatory conditions such as atopic dermatitis (AD) is challenging, and depends on which disease aspects disease are considered to be important, by whom, along with how and when to measure them. A criticism of treat-to-target is its one-size-fits-all approach. Patients/carers may have different preferences on what is important for them, and what is a worthwhile gain when traded-off against the harms and inconvenience of particular treatments.</p><p>To address these limitations of a treat-to-target approach, the AHEAD (Aiming High in Eczema/Atopic Dermatitis) international group sought to identify <i>what</i> aspects of atopic dermatitis (AD) might be included in a treat-to-target approach and <i>how</i> they might be measured.<span><sup>1</sup></span> The group's previous survey identified the most significant symptoms for adult AD patients, how they are measured and treatment expectations. The group used that data to draft a series of treatment recommendations that were subject to a Delphi survey involving 77 AD experts. Unusually, consensus was reached for all 34 recommendations after just one voting round. The group suggest that patients should identify between one to three from six features selected by the AD experts (itch, skin appearance, sleep disturbance, mental health, skin pain and daily life impact). The clinician also chooses an additional objective assessment of disease control. Targets for both optimal and moderate control are suggested for these outcomes for 3–6 months, and monitored with a recommended instrument chosen by the clinician.</p><p>What I liked about this initiative was the attempt to combine the best of both worlds—retaining more ambitious treatment targets for people with AD with some input from patients on what to measure and how. The proposed outcomes align with clinical practice outcomes from the Harmonising Outcomes Measures for Eczema (HOME) initiative.<span><sup>2</sup></span> I also liked the flexibility for moderate as well as optimal control.</p><p>What was missing was lack of consideration of other crucial aspects that govern treatment choices for patients including adverse effects, inconvenience, access and costs. Although adverse effects may be treatment-specific, balancing benefits and harms is a mandatory part of shared decision-making as exemplified in AD patient decision aids.<span><sup>3</sup></span> The preceding adult patient qualitative work, sponsored by AbbVie and cited only in abstract form, was useful but limited, as young people and children/carers where AD is commonest were not included. Although the adult qualitative study was considered when drafting the initial AHEAD recommendations, the complete absence of patient/carer involvement in the final recommendations was disappointing. Other initiatives such as HOME have found that ","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"38 11","pages":"2051-2052"},"PeriodicalIF":8.4,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20298","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142502885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editor's Picks November 2024","authors":"","doi":"10.1111/jdv.20337","DOIUrl":"10.1111/jdv.20337","url":null,"abstract":"<p>Although acute urticaria (AU) is highly prevalent (Figure 1), limited evidence and recommendations exist. According to a review by Badloe et al., corticosteroid addition to a second-generation oral H1-antihistamine did not improve acute urticaria symptoms in two out of three RCTs, and combination of a first-generation H1-antihistamine and H2-antihistamine (intravenously) was most effective for urticaria relief in two out of five studies.</p><p>Emek Kocatürk</p><p>Badloe FMS, Grosber M, Ring J, Kortekaas Krohn I, Gutermuth J. Treatment of acute urticaria: a systematic review. <i>J Eur Acad Dermatol Venereol</i> 2024;38:2082–2092. https://doi.org/10.1111/jdv.19904.</p><p>Chronic Nodular Prurigo (CNPG) is a pruritic skin condition with frequent comorbidities, characterized by the development of nodules due to scratching.</p><p>Pereira et al. evaluated the association between clinically relevant comorbidities (e.g. diabetes and hypertension), itch intensity, and quality of life (QoL) impairment in 513 adults with CNPG treated in 12 European countries (Figure 2). Conditions not typically involved in the pathophysiology of itch also appeared to be related to the perception of itch. Careful management of comorbidities in patients with CNPG is important to potentially alleviate itch intensity and improve QoL.</p><p>Pereira MP, Gutsche A, Weisshaar E, et al. Chronic nodular prurigo: association between comorbidities, itch and quality of life. <i>J Eur Acad Dermatol Venereol</i> 2024;38:e984–e988. https://doi.org/10.1111/jdv.20038.</p><p>International expert dermatologists drafted the Aiming High in Eczema/Atopic Dermatitis (AHEAD) recommendations, suggesting that disease severity should be assessed using both physician-reported and patient-reported outcomes. Physicians should discuss results with patients/caregivers, aiming for targets to optimize patient outcomes. The ultimate treatment goal is a satisfied patient with minimal impact on QoL, clear/almost-clear skin, and no/minimal itch.</p><p>They also established a novel, patient-centred, minimal disease activity (MDA) concept, where patients/caregivers choose one to three atopic dermatitis symptoms/features most important to them, physicians select corresponding patient-reported outcome measures, and both discuss optimal targets (Figure 3).</p><p>Silverberg JI, Gooderham M, Katoh N, et al. Combining treat-to-target principles and shared decision-making: international expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. <i>J Eur Acad Dermatol Venereol</i> 2024;38:2139–2148. https://doi.org/10.1111/jdv.20229.</p><p>Vindenes et al. assessed the understudied relationship between the microbiome and self-reported hand eczema, hand hygiene practices, and moisturizer use. Individuals with hand eczema (HE) showed a more dysbiotic bacterial community over time, with an increase in Staphylococcus associated with active HE. Frequent hand washing","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"38 11","pages":"2043-2044"},"PeriodicalIF":8.4,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20337","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142502887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of hand eczema","authors":"P. V. Chernyshov","doi":"10.1111/jdv.20296","DOIUrl":"10.1111/jdv.20296","url":null,"abstract":"<p>Hand eczema (HE) is a widespread chronic inflammatory skin disease often with multiple provoking factors (e.g. professional), subjective complaints and with lesions located on visible areas. All of these lead to a severe negative impact of HE on patients' lives. Siewertsen et al.<span><sup>1</sup></span> have presented the results of a systematic review and meta-analysis on anxiety, depression and quality of life impairment in patients with HE.</p><p>The authors<span><sup>1</sup></span> were concerned that different measures of HE severity, quality of life and depression were used across their selected studies, complicating comparability. However the same dermatology-specific quality of life instrument, the Dermatology Life Quality Index (DLQI), was used in 82% of their included studies. The DLQI is the most widely used QoL instrument in dermatology both for general use and in the majority of individual skin diseases. Many national and international guidelines recommend QoL assessment in dermatology and some of them contain detailed recommendations on treatment goals and changes of treatment approaches based on DLQI score banding and minimal clinically important difference (MCID).<span><sup>2</sup></span> The meta-analysis by Siewertsen et al.<span><sup>1</sup></span> revealed that the mean DLQI scores of patients with HE corresponds to the lower range of the ‘very large effect on patient's life’ DLQI score band meaning descriptors. Interpretation of the scores and the ‘minimally important change’ for a disease-specific quality of life instrument for hand eczema (QOLHEQ) have been proposed.<span><sup>3</sup></span> However, as pointed out by Siewertsen et al.,<span><sup>1</sup></span> to date only a few studies have used this instrument.</p><p>In patients with HE, scores of various disease severity measures correlated significantly with quality of life impairment scores, using the DLQI. This is also seen in other chronic inflammatory skin diseases. Generic health-related quality of life instruments may be used in any disease and in healthy individuals. The EuroQol-5D visual analogue scale scores demonstrated more impaired QoL in HE patients than in healthy controls, as did the separate domain scores of the Short Form-36.<span><sup>1</sup></span></p><p>Siewertsen et al.<span><sup>1</sup></span> mentioned among the limitations of their systematic review that they were not able to assess differences between male and female patients. However, a large international multicentre study previously demonstrated that only female patients with HE had higher scores for depression and anxiety than controls.<span><sup>4</sup></span> In this context it is especially interesting that the meta-analysis by Siewertsen et al.<span><sup>1</sup></span> revealed significantly higher levels of anxiety in HE patients than in controls, but similar levels of depression.</p><p>Data on the association between HE and suicidal ideation when comparing patients with HE with he","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"38 11","pages":"2049-2050"},"PeriodicalIF":8.4,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20296","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142502889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fears for tears? Targeted therapies for atopic dermatitis and ocular surface health","authors":"Carolyn Jack, Aaron M. Drucker","doi":"10.1111/jdv.20356","DOIUrl":"10.1111/jdv.20356","url":null,"abstract":"<p>Dupilumab is a monoclonal antibody that binds the IL-4 receptor alpha to block a key cytokine axis in atopy, with an excellent safety profile from infancy through old age. In a minority of patients with atopic dermatitis (AD), Dupilumab can be associated with worsening or new inflammation at the surface of the eye.<span><sup>1</sup></span> For most patients, this adverse event is mild or readily managed; but for some, it can lead to Dupilumab discontinuation. Reguiai et al.<span><sup>1</sup></span> have sought to describe this population with a 12-site French collaborative study and contribute new real-world information that may help to address ongoing gaps in knowledge at this ocular epithelial frontier.</p><p>The ocular surface is a dynamic mucosal system that provides lubrication to the eye as well as physical and immunological defence, see Figure 1a. Common criteria for AD include five features involving the eyes: conjunctivitis, keratoconus, cataracts and two signs of peri-orbital skin changes. Conjunctivitis is prevalent in nearly one third of AD patients, and there may be a causal effect from the skin to the eyes.<span><sup>2</sup></span> Shi et al.<span><sup>3</sup></span> recently provided an excellent overview of ocular surface disease (OSD), comprehensive of pathobiology and clinical outcomes in AD patients. More than half of adult AD patients eligible for systemic therapies may suffer from eye symptoms such as pruritus, and a majority can show signs of blepharitis and conjunctivitis, where the hidden palpebral conjunctiva is more commonly affected than that covering the orbit.<span><sup>4</sup></span> These findings may account for the higher rates of ocular adverse effects in pivotal Dupilumab studies for AD, versus asthma or nasal polyposis.<span><sup>3</sup></span></p><p>The Reguiai cohort included 83 patients (7.5% of 1109 Dupilumab-treated patients) who developed OSD leading to treatment switch; 71 patients were captured in follow-up, and 73% were assessed by ophthalmology (Figure 1b).<span><sup>1</sup></span> Most cases were mild–moderate forms of blepharo-conjunctivitis, the subtype of OSD most strongly associated with AD.<span><sup>1, 3</sup></span> Sixty-five % of patients were initially switched to a JAK inhibitor (JAKi) and 35% to the anti-IL-13 biologic Tralokinumab.<span><sup>1</sup></span> Although 30% of patients were subsequently switched again, 68% remained on a JAKi and 7% restarted Dupilumab.<span><sup>1</sup></span> At the end of the study, nearly one quarter of OSD patients had persistent disease, with slightly more still using topical therapies.<span><sup>1</sup></span> While the sample size of the cohort is small, leading to wide confidence intervals for the regression analyses, they did find significantly increased odds for complete resolution associated with switching to a JAKi.<span><sup>1</sup></span>.</p><p>Recent studies have helped initiate a mechanistic framework for understanding Dupilumab-associated","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"38 11","pages":"2053-2055"},"PeriodicalIF":8.4,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20356","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142502888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diving beyond surface perceptions of melanoma diagnosis and screening","authors":"Efthymia Soura, Alexander Stratigos","doi":"10.1111/jdv.20227","DOIUrl":"10.1111/jdv.20227","url":null,"abstract":"<p>During the last few years, there have been significant changes in the diagnosis of melanoma. This new era was ushered by the introduction of dermoscopy, digital dermoscopy and other skin imaging techniques and is continuing to thrive with the addition of innovative artificial intelligence applications. However, a new question has recently arisen: Have these improvements positively affected patient outcomes and survival? Unfortunately, the answer to this question may not be so simple.</p><p>The Schleswig-Holstein (Germany) initiative famously yielded ambiguous results. A total of 360,000 people were screened with 90% of melanomas detected being less than 1 mm thick. 5 years following the 12-month screening effort, overall melanoma mortality seemed to decline while in adjacent geographic areas there were no changes. Unfortunately, the initial mortality decline was not sustained; 2 years later, mortality rates returned to the pre-screening level.<span><sup>1</sup></span> The U.S. Preventive Services Task Force published an evidence update on available data regarding melanoma prevention and screening.<span><sup>2</sup></span> Screening was not considered harmful for patients, but no direct benefit was demonstrated in regard to survival. Overall, the evidence was inconsistent, but an association of screening with diagnosing thinner lesions could be made.<span><sup>2</sup></span> One of the few studies that compared melanoma trends between screened and unscreened patients, reported that screened patients were more likely to be diagnosed with in situ melanoma (MIS) or thin invasive (≤1 mm) melanoma.<span><sup>3</sup></span></p><p>Overdiagnosis is not a new concept in the epidemiology of cancer. A recent meta-analysis has shown that up to 27% and 17% of breast and ovarian cancer may be overdiagnosed.<span><sup>4</sup></span> In addition, for every life saved due to breast cancer screening, there are 136 false positives, 21 redundant biopsies and 3 overdiagnoses.<span><sup>5</sup></span> Interesting data about lung, liver, breast, ovarian and prostate cancers are provided, but melanoma is nowhere to be found.<span><sup>4</sup></span> This exclusion is not based in discrimination against skin cancer but simply in a lack of robust epidemiologic data. There are no randomized clinical trials regarding melanoma and therefore, at this time, there is no way to quantify the outcomes of skin cancer screening efficiently.</p><p>With regard to melanoma, there are no official guidelines on who to screen and how often. In addition, dermatology seems to be a popular medical specialty as a recent study reported dermatologists as the second most often visited specialists in a 24-month interval and the first healthcare providers for skin cancers in most European countries. As a matter of fact, naevi check-up or skin cancer screening was the most common reason for visiting a dermatologist.<span><sup>6</sup></span> The Schleswig-Holstein initiative reported that 620 peop","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"38 11","pages":"2045-2046"},"PeriodicalIF":8.4,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.20227","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142502886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ApreScalp: A Phase 4 multicentre, randomized, placebo-controlled study evaluating the effect of apremilast on pruritus and quality of life of patients with moderate-to-severe scalp psoriasis.","authors":"Sara E Cerminara, Ivana Cvijetic, Stephanie Huber, Simon Müller, Lisa Kostner, Elisabeth V Goessinger, Jasmin Narainsing, Gilles Dutilh, Kristine Heidemeyer, Nikhil Yawalkar, Curdin Conrad, Tobias Plaza, Julia-Tatjana Maul, Antonio Cozzio, Alexander A Navarini","doi":"10.1111/jdv.20400","DOIUrl":"https://doi.org/10.1111/jdv.20400","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142502877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on 'Efficacy and tolerance of dupilumab in patients with moderate-to-severe atopic dermatitis and obesity' by Dupuis et al.","authors":"Luca Potestio, Cataldo Patruno, Francesca di Vico, Luciano Foggia, Maddalena Napolitano","doi":"10.1111/jdv.20404","DOIUrl":"https://doi.org/10.1111/jdv.20404","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142502879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Declining invasive and rising in situ melanoma incidence trends in Iceland: A nationwide cohort study.","authors":"Sierra Thomas, David Hoyt, Gregory Stoddard, Ashley M Snyder, Eir Andradottir, Jane M Grant-Kels, Jonathan Ungar, Jesse M Lewin, Nicholas Gulati, Jon Gunnlaugur Jonasson, Helgi Sigurdsson, Hildur Helgadottir, Jonas A Adalsteinsson","doi":"10.1111/jdv.20386","DOIUrl":"https://doi.org/10.1111/jdv.20386","url":null,"abstract":"<p><strong>Background: </strong>Melanoma is increasing worldwide, with incidence rates of invasive melanoma and melanoma in situ (MIS) varying by country.</p><p><strong>Objective: </strong>To provide updated invasive melanoma and MIS incidence and mortality trends in Iceland and explore differences among sex and rurality.</p><p><strong>Methods: </strong>In this whole-population study using the Icelandic Cancer Registry, patients diagnosed with invasive melanoma or MIS between 1957 and 2021 were included. Sex-specific world standardized incidence (WSR) and mortality rates were assessed by rurality. Joinpoint analysis was used to calculate trends using annual per cent change (APC).</p><p><strong>Results: </strong>Invasive melanoma incidence rates increased from 0.66 to 7.0 (men) and 1.6 to 11.0 (women) per 100,000 person-years, and from 0.2 to 4.0 and 0.9 to 9.5 per 100,000 person-years for MIS in men and women, respectively, with a statistically significant linear trend (p = 0.001). WSR peaked in both men and women (10.7, 17.9 per 100,000 person-years) between 2002 and 2006 and has since been trending down. Between 1991 and 2005, the rise in invasive melanoma occurred more frequently in urban regions. Between 2003 and 2005, joinpoint analysis demonstrated a downtrend in invasive melanoma in men and women (-0.29, -0.73; p < 0.05). For MIS, the WSR peaked at 12.4 per 100,000 person-years in women between 1997 and 2001 before down-trending to 4.2. In recent years (2017-2021), the WSR has been steadily increasing in women with an APC of 1.43. Melanoma-specific mortality has decreased since 2012 (-0.07; p < 0.05).</p><p><strong>Conclusions: </strong>Declining invasive melanoma incidence and mortality rates in conjunction with the recent rise in MIS may reflect the impact of Iceland's sun safety and anti-sunbed educational campaigns, federal regulation of sunbeds and earlier melanoma detection in urban areas.</p>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142502880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata.","authors":"D Aceituno, C G Fawsitt, G M Power, E Law, S Vaghela, H Thom","doi":"10.1111/jdv.20372","DOIUrl":"https://doi.org/10.1111/jdv.20372","url":null,"abstract":"<p><p>Ritlecitinib and baricitinib are recently approved systemic treatments for severe alopecia areata (AA). Both demonstrated superiority over placebo in hair regrowth measured by the Severity of Alopecia Tool (SALT), but they have not been directly compared in randomized controlled trials (RCTs). We conducted a systematic review of RCTs evaluating treatments in AA and estimated the efficacy and safety of ritlecitinib and baricitinib at Week 24 using Bayesian network meta-analysis. To adjust and explore effect modifiers, population-adjusted indirect comparison was performed via multilevel network meta-regression (ML-NMR) using ritlecitinib individual patient data (IPD). Co-primary endpoints were SALT ≤20 and SALT ≤10 at Week 24. Unanchored population adjusted ITCs were also computed to evaluate SALT ≤10 and SALT ≤20 endpoints at Week 48/52. Four RCTs (ALLEGRO 2a [NCT02974868], ALLEGRO 2b/3 [NCT03732807], BRAVE-AA1 [NCT03570749] and BRAVE-AA2 [NCT03899259]) were included. No evidence of a difference between ritlecitinib 50 mg and baricitinib 4 mg on SALT ≤10 (odds ratio, OR: 0.96, 95% credible interval, CrI: 0.18-7.21) and SALT ≤20 (OR: 2.16, 95% CrI: 0.48-16.46) at Week 24 was found. ML-NMR using ALLEGRO IPD adjusted for sex, SALT score at baseline, duration of current episode and disease duration found evidence of effect modification, although relative efficacy between ritlecitinib 50 mg and baricitinib 4 mg remained unchanged. Unanchored population-adjusted ITC at Week 48/52 was consistent with previous results. We found similar efficacy between ritlecitinib 50 mg and baricitinib 4 mg. These ITCs was informed by only four RCTs, uncertainty was considerable, and there was evidence of effect modification, highlighting the need for further quality research in AA.</p>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142502883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing dermatologists-venereologists' awareness, vigilance and attitude towards LGBT individuals: A cross-sectional study in Greece.","authors":"Aikaterini Tsentemeidou, Nikolaos Chaitidis, Ilias Papadimitriou, Vasileios Paraschou, Themis Chatzi-Sotiriou, Olga Pikou, Dimitra Kiritsi, Efstratios Vakirlis, Elena Sotiriou","doi":"10.1111/jdv.20393","DOIUrl":"https://doi.org/10.1111/jdv.20393","url":null,"abstract":"","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142502878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}